All In Biotech

Drug Trial Radar · NCT06524414

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants

A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 605 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

605

Actual

Start

Jul 25, 2024

Primary completion

Mar 4, 2027

Study completion Mar 4, 2027

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jul 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 42 days, up to 98 days
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs in infants when compared to the pneumococcal vaccines that are currently in use, 20vPnC (Prevnar 20®) or another licensed pneumococcal vaccine. To ensure that the new vaccine (PG4) stays stable, it is placed in a liquid mixture of sterile water and other substances (a solution). This study will also test if there is a difference in the safety and immune effects of the new pneumococcal vaccine when it is one type of solution compared to when it is in a different type of solution. The immune response is how the body's cells; tissues and organs work together to protect the body from infection. Blood samples will be used to measure the amount of antibodies produced after the vaccination. Antibodies are proteins that protect you when an unwanted germ enters the body. This will help understand how well the new pneumococcal vaccine works. This vaccine can possibly provide protection against pneumococcal disease. Pneumococcal disease includes a variety of infections caused by a specific germ, Streptococcus pneumoniae. This study is seeking participants who are: * male or female infants who are 2 months of age, * infants born at 36 weeks (about 8 and a half months) of pregnancy or later; and, * said to be healthy by the study doctor There are four groups in this study. All participants will be assigned to one of the four groups. All study vaccines will be given as a single shot into the left thigh muscle. Participants in the three groups will have 3 blood samples collected during the 1 and a half years they are in the study. The first 400 participants who enter the study will be assigned to either Group 1 or Group 2. Half the participants in Group 1 and half the participants in Group 2 will receive 4 doses at 2, 4, 6, and 12 to 15 months of age of PG4 mixed in the first solution. The other half of the participants in Groups 1 and 2 will receive 4 doses of 20vPnC (Prevnar 20®) at 2, 4, 6, and 12 to 15 months of age. The main difference between Groups 1 and 2 is that participants in Group 2 will have the first blood sample collected at an earlier time than those in Group 1. Once 400 participants have been assigned to Groups 1 and 2 then 100 new participants will be assigned to Group 3. Half the participants in Group 3 will receive PG4 in the second solution at 2, 4, 6, and 12 to 15 months of age. The other half of the participants in Groups 3 will receive 4 doses of 20vPnC (Prevnar 20®) at 2, 4, 6, and 12 to 15 months of age. Once the 100 participants have been assigned to Group 3 then 100 new participants will be assigned to Group 4. Half the participants in Group 4 will receive PG4 in the first solution at 2, 4, 6, and 12 to 15 months of age. The other half of the participants in Group 4 will receive 4 doses of a licensed pneumococcal comparator vaccine at 2, 4, 6, and 12 to 15 months of age. Participants will take part in this study for about 16 to 19 months (about 1 and a half years). During this time, participants will have 6 study clinic visits and 1 to 2 phone calls. At these study clinic visits, parent(s) or legal guardian(s) will be asked if the participant experienced any side effects. A side effect is an unintentional or unexpected reaction to a vaccine.

Conditions

  • Pneumococcal Disease

Interventions

  • PG4Biological

    Multivalent pneumococcal conjugate vaccine

  • 20-valent pneumococcal conjugate vaccine (20vPnC)Biological

    20-valent pneumococcal conjugate vaccine

  • 15-valent pneumococcal conjugate vaccine (PCV15)Biological

    15-valent pneumococcal conjugate vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants reporting local reactions within 7 days after each doseTime frame: Day 7
  2. Percentage of participants reporting systemic events within 7 days after each doseTime frame: Day 7
  3. Percentage of participants reporting adverse events (AEs)Time frame: Dose 1 to 1 month after Dose 3
  4. Percentage of participants reporting AEsTime frame: Dose 4 to 1 month after Dose 4
  5. Percentage of participants reporting serious adverse events (SAEs)Time frame: Dose 1 to 6 months after Dose 4

Locations

67 sites in 2 countries. Site status is shown where the registry gives one.

  • Northwest Arkansas Pediatric Clinic

    Fayetteville, Arkansas

  • The Children's Clinic

    Jonesboro, Arkansas

  • Los Ninos Children's Medical Clinic

    La Puente, California

  • Los Ninos Children's Medical Clinic

    West Covina, California

  • Velocity Clinical Research, Washington DC

    Washington D.C., District of Columbia

  • Riveldi Biomedical Research and Associates - Miami

    Miami Lakes, Florida

  • Clinical Research Prime

    Idaho Falls, Idaho

  • The Iowa Clinic

    Ankeny, Iowa

  • Cotton O'Neil Pediatrics

    Topeka, Kansas

  • Kentucky Pediatric/ Adult Research

    Bardstown, Kentucky

  • All Children Pediatrics

    Louisville, Kentucky

  • Bluegrass Clinical Research, Inc.

    Louisville, Kentucky

  • LSUHSC Clinical Trials Office

    Shreveport, Louisiana

  • Louisiana State University Health Sciences Shreveport

    Shreveport, Louisiana

  • Ochsner/LSU Health Ambulatory Care Center

    Shreveport, Louisiana

  • University of Maryland

    Baltimore, Maryland

  • UMB/CVD

    Frederick, Maryland

  • Pediatric Associates of Fall River

    Fall River, Massachusetts

  • Boeson Research GTF

    Great Falls, Montana

  • OBGYN Associates

    Great Falls, Montana

  • Origin Health

    Great Falls, Montana

  • Boeson Research KAL

    Kalispell, Montana

  • Heart and Hands Midwifery and Family Practice

    Kalispell, Montana

  • POEM Healthcare

    Kalispell, Montana

  • Blue Moose Pediatrics

    Missoula, Montana

  • Boeson Research Laboratory

    Missoula, Montana

  • Boeson Research MSO

    Missoula, Montana

  • Midwest Children's Health Research Institute

    Lincoln, Nebraska

  • Child Health Care Associates

    East Syracuse, New York

  • University of Rochester

    Rochester, New York

  • University of Rochester Medical Center

    Rochester, New York

  • Velocity Clinical Research Inc.

    Durham, North Carolina

  • Duke Vaccine and Trials Unit

    Durham, North Carolina

  • Durham Pediatrics at North Duke Street

    Durham, North Carolina

  • Dayton Clinical Research

    Dayton, Ohio

  • Ohio Pediatric Research Assn.

    Dayton, Ohio

  • Senders Pediatrics

    South Euclid, Ohio

  • Cyn3rgy Research

    Gresham, Oregon

  • Allegheny Health and Wellness Pavilion

    Erie, Pennsylvania

  • Square-1 Clincal Research

    Erie, Pennsylvania

Showing 40 of 67 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.